Tammy Lee has more than 15 years of executive experience and currently serves as President and CEO for Recombinetics, a global leader in gene-edited animals for biomedical research; animal welfare; and safe, healthy food production.
Tammy brings a breadth and depth of business experience to the role of CEO. She’s held senior executive roles in large, complex, multinational businesses including Vice President of Corporate Affairs at Carlson companies, a global leader in hospitality and travel. She was Vice President of Corporate Affairs for Delta Air Lines during Northwest-Delta merger and previously served as a corporate officer for Northwest Airlines and Sun Country Airlines.
Tammy is currently a member of the Women Presidents Organization, Minnesota Women’s Economic Roundtable and Women’s Forum of Minnesota.
Tammy has an MBA from the University of St. Thomas in St. Paul, Minn. and serves on the Board of Regents for her alma mater, Concordia College, where she received bachelor of arts degrees in political science and communications.
About Recombinetics: Recombinetics’ proprietary technology platform supports three business lines: Surrogen (biomedical swine models that replicate human disease); Regenevida (regenerative cells, tissues and organ products); and Acceligen (accelerated, precision breeding in animal agriculture). Recombinetics has a global intellectual property portfolio, with 16 patents issued and more than 200 patent filings on gene-editing methods, traits, and novel reproduction methods in animals.